Launch and Preliminary Analysis of Hospital de La Princesa's Inter-specialists Biological Therapies Unit

Smolen, 2007, New therapies for treatment of rheumatoid arthritis, Lancet, 370, 1861, 10.1016/S0140-6736(07)60784-3 Sandborn, 2012, The future of inflammatory bowel disease therapy: where do we go from here?, Dig Dis, 30, 140, 10.1159/000342742 Sandoval, 2014, Systemic therapies for psoriasis: an evidence-based update, Am J Clin Dermatol, 15, 165, 10.1007/s40257-014-0064-x Arnason, 2005, Long-term experience with interferon beta-1b (Betaferon) in multiple sclerosis, J Neurol, 252, iii28 Lubrano, 2014, Tumour necrosis factor alpha inhibitor therapy and rehabilitation for the treatment of ankylosing spondylitis: a systematic review, Semin Arthritis Rheum Ford, 2011, Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis, Am J Gastroenterol, 106, 644, 10.1038/ajg.2011.73 Rieckmann, 2004, Escalating immunotherapy of multiple sclerosis – new aspects and practical application, J Neurol, 251, 1329, 10.1007/s00415-004-0537-6 Mauskopf, 2014, Treatment sequencing after failure of the first biologic in cost-effectiveness models of psoriasis: a systematic review of published models and clinical practice guidelines, Pharmacoeconomics, 32, 395, 10.1007/s40273-014-0130-5 Ramiro, 2014, Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis, Ann Rheum Dis, 73, 529, 10.1136/annrheumdis-2013-204575 Schmitt, 2014, Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials, Br J Dermatol, 170, 274, 10.1111/bjd.12663 Norton, 1993, Application of transient evoked otoacoustic emissions to pediatric populations, Ear Hear, 14, 64, 10.1097/00003446-199302000-00009 Maese, 2012, Management of rheumatoid arthritis in Spain (emAR II). Clinical characteristics of the patients, Reumatol Clin, 8, 236, 10.1016/j.reuma.2012.03.009 Loza, 2007, Variability in the use of orthopedic surgery in patients with rheumatoid arthritis in Spain, J Rheumatol, 34, 1485 Cawson, 2014, Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis, BMC Musculoskelet Disord, 15, 26, 10.1186/1471-2474-15-26 Chen, 2006, A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness, Health Technol Assess, 10, 10.3310/hta10420 Dretzke, 2011, A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-alpha) inhibitors, adalimumab and infliximab, for Crohn's disease, Health Technol Assess, 15, 1, 10.3310/hta15060 Carmona, 2014, BIOBADASER, BIOBADAMERICA, and BIOBADADERM: safety registers sharing commonalities across diseases and countries, Clin Exp Rheumatol, 32 Vermeer, 2011, Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study, Arthritis Rheum, 63, 2865, 10.1002/art.30494 Cabriada, 2013, Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease, Gastroenterol Hepatol, 36, 127, 10.1016/j.gastrohep.2013.01.002 Gonzalez-Alvaro, 2014, Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, Rheumatology (Oxford) Carrascosa, 2014, Drug survival in biologic therapy. Do we know what it means? Can we calculate it?, Actas Dermosifiliogr, 105, 729, 10.1016/j.ad.2014.04.004 Garcia Merino, 2010, Spanish Neurology Society consensus document on the use of drugs in multiple sclerosis: escalating therapy, Neurologia, 25, 378